DaVita Inc. (DVA) Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers DaVita Inc.'s unaudited financial results for the quarterly period ended September 30, 2024. DaVita is a leading provider of kidney dialysis services in the United States, operating through its U.S. dialysis segment and ancillary services (including Integrated Kidney Care and international operations). The company reported as a large accelerated filer with approximately 82.0 million shares of common stock outstanding as of October 25, 2024.
Key Financial Metrics
| Metric (in millions) | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Total Revenues | $3,264 | $3,121 | $9,521 | $8,994 |
| Operating Income | $535 | $496 | $1,525 | $1,213 |
| Net Income (Total) | $296 | $309 | $901 | $726 |
| Net Income Attributable to DaVita | $215 | $247 | $677 | $541 |
| Diluted EPS (DaVita) | $2.50 | $2.62 | $7.66 | $5.80 |
| Operating Cash Flow (YTD) | $1,474 (vs. $1,574 YTD 2023) | |||
| Free Cash Flow (YTD) | $882 (vs. $979 YTD 2023) | |||
| Total Debt (Principal) | $9,624 (as of Sept 30, 2024) | |||
| Cash & Equivalents | $1,071 (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 4.6% year-over-year (YTD) and 2.3% quarter-over-quarter. U.S. dialysis revenue grew 4.6% YTD, driven by higher average reimbursement rates and treatment volume growth. Ancillary services revenue grew 15.1% YTD, primarily due to international expansion.
- Profitability: Operating income increased 25.7% YTD. However, Net Income attributable to DaVita decreased 13% in Q3 compared to Q3 2023, largely due to higher debt expense and increased noncontrolling interest allocations.
- Debt Restructuring: The company significantly restructured its debt profile in 2024. It issued $1.0 billion in 6.875% Senior Notes due 2032 and increased its Term Loan A-1 by $1.1 billion. These proceeds were used to prepay the remaining Term Loan B-1 balance ($950 million) and the revolving line of credit.
- Share Repurchases: DaVita repurchased 7.5 million shares for approximately $1.02 billion during the first nine months of 2024, a significant increase from zero repurchases in the same period in 2023.
- Center Closures: The company incurred approximately $48.2 million in charges related to U.S. dialysis center closures YTD 2024, compared to $67.3 million in YTD 2023, as part of ongoing footprint optimization.
Guidance, Outlook, and Risks
- Operational Outlook: Management notes that treatment volumes remain flat due to elevated patient mortality rates and missed treatments driven by severe weather events. The company continues to face inflationary pressures on labor and supply costs.
- Change Healthcare (CHC) Impact: The CHC cybersecurity outage in early 2024 caused delays in claims processing and collections. While claims submission has resumed, the company continues to experience delays in collections with some payors, impacting Days Sales Outstanding (DSO).
- Supply Chain Disruptions: Hurricane Helene damaged a key Baxter International manufacturing facility, causing shortages in critical supplies (saline and peritoneal dialysate). DaVita has implemented conservation measures and paused new starts for home-based peritoneal dialysis.
- Legal and Regulatory: The company is subject to various investigations, including a 2017 U.S. Attorney Colorado investigation (settled for $34.5 million in May 2024) and ongoing FTC inquiries regarding non-compete clauses. Management expects continued legal expenses and potential regulatory changes.
- Liquidity: As of September 30, 2024, the company had $1.5 billion available under its undrawn revolving credit facility and $1.07 billion in cash and cash equivalents. Management believes liquidity is sufficient to fund operations and debt service for the next 12 months.
Investor Verification Checklist
- Debt Service Coverage: Verify the impact of the new 6.875% Senior Notes and increased Term Loan A-1 on future interest expense and leverage ratios, given the expiration of lower-cost 2019 interest rate caps.
- CHC Collection Lag: Monitor Days Sales Outstanding (DSO) and cash flow from operations to assess the lingering financial impact of the Change Healthcare outage on commercial and government payor collections.
- Supply Chain Resilience: Track the resolution of Baxter supply shortages and the potential long-term impact on home dialysis growth and patient care continuity.
- Noncontrolling Interest (NCI): Analyze the increasing allocation of net income to noncontrolling interests ($81 million in Q3 2024 vs. $63 million in Q3 2023) and its effect on DaVita's attributable earnings.
- Center Closure Costs: Review the trajectory of center closure charges and the associated impact on depreciation and amortization expenses as the company continues to optimize its footprint.